GlassScriptPhysician profile
Meagan E Rowland
NPI 1700428802
$1,512.92
in general payments reported to CMS, 2019-2025
12 companies · $439 in 2025
The $439 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $562 · 2024: $513 · 2025: $439.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,513.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,512.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $992.54 | 2023-2025 | |
| Qol Medical, LLC | $124.05 | 2023-2025 | Sucraid, Sucraid |
| Ironwood Pharmaceuticals, INC | $80.01 | 2023-2024 | Linzess |
| Celgene Corporation | $79.99 | 2023-2024 | Zeposia |
| Janssen Biotech, INC. | $60.06 | 2023-2025 | Stelara, Tremfya, Simponi Aria |
| Phathom Pharmaceuticals, INC. | $40.10 | 2025 | Voquezna |
| Medtronic, INC. | $39.61 | 2024-2025 | Gi Genius, Pillcam |
| Ardelyx, INC. | $36.18 | 2023 | Ibsrela |
| Takeda Pharmaceuticals U.S.A., INC. | $16.69 | 2024 | Entyvio |
| Pfizer INC. | $15.30 | 2025 | |
| Novo Nordisk INC | $15.13 | 2025 | Wegovy |
| Nestle Healthcare Nutrition INC. | $13.26 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Meagan Rowland listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.